INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is the third most common cause of cancer-related death in the United States \[[@R1]\], and an estimated 134,490 new cases will be diagnosed in 2016 \[[@R2]\]. The 5-year relative survival rate for CRC patients is 65% \[[@R2]\]. The 5-year relative survival rate for stage II CRCs is about 82.5% \[[@R3]\]; thus, approximately 20% of patients with tumors of this stage ultimately die of recurrent disease. Currently, clinical and pathologic stage are the primary bases for selecting therapies for CRC patients. Patients with stage I disease have an excellent prognosis after surgery alone (80% to 95% 5-year survival) \[[@R4]\], while adjuvant chemotherapy improves both disease-free and overall disease-specific survival in patients with stage III disease \[[@R5]\]. However, the use of chemotherapy after curative operation remains controversial in stage II colorectal cancer patients. Stage II CRC patients are generally considered to be at low risk of postoperative recurrence; therefore, routine adjuvant chemotherapy is generally not recommended for these patients \[[@R6]\]. However, a recent study found that stage IIIa CRC patients who received chemotherapy survived longer than stage IIb patients who did not \[[@R3]\]. Identification of reliable prognostic molecular markers for stage II CRC patients is therefore crucial. The ability of current histopathology- and imaging-based staging to predict CRC prognosis is limited, suggesting that molecular classifications should be refined \[[@R7]\].

Defining cancer subtypes based on pathway-driven alterations has the potential to improve prognoses. The chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP) pathways play important roles in CRC tumorigenesis. Although CIN contributes to the majority of CRCs, approximately 15% of tumors develop via MSI \[[@R8]\]. MSI is the abnormal shortening or lengthening of DNA by 1 to 6 repeating base pair units resulting from deficient DNA mismatch repair (dMMR). dMMR can result from germline mutations in MMR genes (*MLH1*, *MSH2*, *MSH6*, and *PMS2*), i.e., Lynch syndrome \[[@R9]\]. However, most instances of dMMR in CRC are due to sporadic epigenetic inactivation of *MLH1* \[[@R10]\]. Methylation of *MLH1* is also a major molecular determinant of CIMP-positive (CIMP+) CRC and is often included in the traditional CIMP markers panel; however, *MLH1* methylation-associated features have not been investigated fully in CIMP+ CRC \[[@R11]\]. The CIMP classification was first proposed in 1999 to describe a subset of CRCs with aberrant methylation of cytosine residues at CpG islands in the promoter regions of multiple cancer-specific genes \[[@R12]\]. From then on, various methylation markers have been developed and used to determine CIMP status in CRC tumors, but these results have been inconsistent and arbitrary. The classic CIMP panel consists of five CIMP markers: *CDKN2A*, *MINT1*, *MINT2*, *MINT31*, and *MLH1*. Weisenberger *et al*. developed a new five-marker panel consisting of *CACNA1G*, *IGF2*, *NEUROG1*, *RUNX3*, and *SOCS1*, and found that it was more accurate in determining CIMP status than the classic panel \[[@R13]\]. Interestingly, *MLH1* methylation has also been detected in some CIMP negative (CIMP−) tumors, and *MLH1-*unmethylated (*MLH1-*U) tumors can be found in CIMP+ CRCs \[[@R12], [@R13]\]. We recently developed a model that combines CIMP makers and *MLH1* methylation status to stratify tumor subtypes and found that it may assist in determining prognosis in duodenal adenocarcinoma patients. Patients with CIMP+/*MLH1-*U tumors had the worst prognoses \[[@R14]\]. In a more recent study, Kim *et al*. found that CIMP+ status in both *MLH1*-methylated (*MLH1-*M) and *MLH1*-U CRC patients was associated with adverse clinicopathologic and molecular features \[[@R11]\].

In this study, we examined associations between tumor subtypes as defined by CIMP/*MLH1* methylation status and clinicopathologic and molecular characteristics, and explored the impact of these subtypes on clinical outcomes. These data may provide further insight into the clinical behavior of CIMP+/*MLH1*-U tumors versus other tumor subtypes and may be useful in patient management and clinical decision-making.

RESULTS {#s2}
=======

Associations between CIMP and *MLH1* methylation status and clinicopathologic characteristics {#s2_1}
---------------------------------------------------------------------------------------------

DNA extraction and CIMP testing using MethyLight were successful in all 115 patients. Twenty-five (21.7%) of the 115 patients tested were CIMP+. Among the CIMP+ tumors, 9 (36.0%) were *MLH1*-U and 16 (64.0%) were *MLH1*-M. Based on CIMP and *MLH1* methylation status, tumors were assigned to CIMP+/*MLH1*-U (*n* = 9), CIMP+/*MLH1*-M (*n* = 16), CIMP−/*MLH1*-U (*n* = 77), and CIMP−/*MLH1*-M (*n* = 13) groups. Among the clinical characteristics examined, the four patient subgroups differed in terms of age (*P* = 0.003), tumor location (*P* = 0.001), lymphovascular invasion (*P* = 0.034), and mucin production (*P* = 0.013; Table [1](#T1){ref-type="table"}). Most patients with CIMP+ tumors (CIMP+/*MLH1*-U and CIMP+/*MLH1*-M groups) were 60 years old or older, especially in the CIMP+/*MLH1*-M group (93.8%). CIMP+/*MLH1*-M tumors were more likely to be proximally located (93.8%), whereas CIMP−/*MLH1*-M tumors were frequently observed in the distal colon and rectum (69.2%). However, both CIMP+/*MLH1*-U and CIMP−/*MLH1*-U tumors had diffuse distribution, with 55.6% and 44.2% located in the proximal colon, respectively (*P* = 0.001). CIMP+/*MLH1*-U tumors were more likely to involve lymphovascular invasion (55.6 versus 12.5--15.4 %; *P* = 0.034) and mucin production (55.6 versus 0--18.2%; *P* = 0.013; Table [1](#T1){ref-type="table"}) than those in the other three groups; these differences remained statistically significant after examination using Fisher\'s exact test (*P* = 0.008 for lymphovascular invasion, *P* = 0.010 for mucin production). No correlations were found between tumor subgroup and molecular features (*KRAS* mutations, *P* = 0.512, MSI status, *P* = 0.919).

###### Differences in clinicopathologic features of colorectal cancer depending on CIMP and *MLH1* methylation status

  Variable                                     Total*n*(*n* = 115)   CIMP+*/MLH1-*U(*n* = 9)   CIMP+/*MLH1-*M(*n* = 16)   CIMP−*/MLH1-*U(*n* = 77)   CIMP−*/MLH1-*M(*n* = 13)   *P*-value
  ------------------------- ------------------ --------------------- ------------------------- -------------------------- -------------------------- -------------------------- -----------
  Age                       \< 60              38 (33.0)             2 (22.2)                  1 (6.3)                    26 (33.8)                  9 (69.2)                   0.003
                            ≥ 60               77 (67.0)             7 (77.8)                  15 (93.8)                  51 (66.2)                  4 (30.8)                   
  Sex                       Male               52 (45.2)             4 (44.4)                  7 (43.8)                   37 (48.1)                  4 (30.8)                   0.735
                            Female             63 (54.8)             5 (55.6)                  9 (56.3)                   40 (51.9)                  9 (69.2)                   
  Location                  Proximal           58 (50.4)             5 (55.6)                  15 (93.8)                  34 (44.2)                  4 (30.8)                   0.001
                            Distal             57 (49.6)             4 (44.4)                  1 (6.3)                    43 (55.8)                  9 (69.2)                   
  Lymph nodes examined      ≥ 12               80 (69.6)             7 (77.8)                  13 (81.3)                  49 (63.6)                  11 (84.6)                  0.236
                            \< 12              35 (30.4)             2 (22.2)                  3 (18.8)                   28 (36.4)                  2 (15.4)                   
  Differentiation           Well to moderate   95 (82.6)             6 (66.7)                  12 (75.0)                  66 (85.7)                  11 (84.6)                  0.363
                            Poor               20 (17.4)             3 (33.3)                  4 (25.0)                   11 (14.3)                  2 (15.4)                   
  pT4                       No                 103 (89.6)            8 (88.9)                  16 (100)                   68 (88.3)                  11 (84.6)                  0.496
                            Yes                12 (10.4)             1 (11.1)                  0 (0)                      9 (11.7)                   2 (15.4)                   
  Lymphovascular invasion   No                 95 (82.6)             4 (44.4)                  14 (87.5)                  66 (85.7)                  11 (84.6)                  0.034
                            Yes                20 (17.4)             5 (55.6)                  2 (12.5)                   11 (14.3)                  2 (15.4)                   
  Mucin production          No                 94 (81.7)             4 (44.4)                  14 (87.5)                  63 (81.8)                  13 (100.0)                 0.013
                            Yes                21 (18.3)             5 (55.6)                  2 (12.5)                   14 (18.2)                  0 (0)                      
  *KRAS*                    Wild type          75 (65.2)             4 (44.4)                  10 (62.5)                  53 (68.8)                  8 (61.5)                   0.512
                            Mutant             40 (34.8)             5 (55.6)                  6 (37.5)                   24 (31.2)                  5 (38.5)                   
  MSI status                MSS + MSI-low      59 (51.3)             5 (55.6)                  7 (43.8)                   40 (51.9)                  7 (53.8)                   0.919
                            MSI-high           56 (48.7)             4 (44.4)                  9 (56.3)                   37 (48.1)                  6 (46.2)                   

Abbreviations: CIMP+, CpG island methylator phenotype positive; CIMP−, CpG island methylator phenotype negative; *MLH1*-U, *MLH1*-unmethylated; *MLH1*-M, *MLH1-*methylated; MSI, microsatellite instability

Survival is poorest in CRC patients with CIMP+/*MLH1*-U tumors {#s2_2}
--------------------------------------------------------------

Kaplan-Meier survival curves were generated based on CIMP and *MLH1* methylation status. For the overall patient cohort, median disease-free survival (DFS) and overall survival (OS) were 82.6 months (95% CI, 64.0--101.2) and 88.6 months (95% CI, 42.5--134.7), respectively. Five-year DFS and OS rates were 62.6% and 73.6%, respectively. Both DFS (*P* = 0.008; Figure [1A](#F1){ref-type="fig"}) and OS (*P \<* 0.001; Figure [1B](#F1){ref-type="fig"}) differed among the four CIMP/*MLH1* methylation subgroups. Median DFS and OS were 20.6 months (95% CI, 0--41.9) and 41.7 months (95% CI, 28.0--55.4) for the CIMP+/*MLH1*-U group, 70.3 months (95% CI, 37.1--103.5) and 70.3 months (95% CI, 37.6--103.0) for the CIMP+/*MLH1*-M group, and 83.5 months (95% CI, 45.1--121.9) and 91.6 months (95% CI, 45.1--138.1) for the CIMP−/*MLH1*-U group; median DFS and OS could not be reached for the CIMP−/*MLH1*-M group. DFS and OS were shorter for CIMP+/*MLH1*-U group patients than for patients in each of the other three groups (versus the CIMP+/*MLH1*-M group: *P* = 0.046 for DFS, *P* = 0.046 for OS; versus the CIMP−/*MLH1*-U group: *P* = 0.001 for DFS, *P \<* 0.001 for OS; versus the CIMP−/*MLH1*-M group: *P* = 0.016 for DFS, *P* = 0.003 for OS). DFS and OS were also dramatically shorter in patients with CIMP+/*MLH1*-U tumors compared to the other three patient groups combined (*P* = 0.001 for DFS, *P \<* 0.001 for OS, respectively; Figure [2A, 2B](#F2){ref-type="fig"}).

![Kaplan-Meier survival estimates in stage II colorectal cancer patient groups classified by CIMP/*MLH1* methylation status\
(**A**) Disease-free survival, (**B**) Overall survival. *P* values were calculated using the log-rank test.](oncotarget-07-86480-g001){#F1}

![Kaplan-Meier survival estimates in stage II colorectal cancer patients with CIMP+/*MLH1*-unmethylated tumors compared to the remaining three patient groups\
(**A**) Disease-free survival, (**B**) Overall survival. *P* values were calculated using the log-rank test.](oncotarget-07-86480-g002){#F2}

Univariate and multivariate analyses of outcome predictors {#s2_3}
----------------------------------------------------------

Next, we conducted univariate and multivariate analyses using a Cox proportional hazards model to examine associations between sex, number of lymph nodes examined, pT4, lymphovascular invasion, tumor location, differentiation, *KRAS* mutations, MSI, and CIMP/*MLH1* status (CIMP+/*MLH1*-U or other subtypes) and DFS and OS (Table [2](#T2){ref-type="table"}). In univariate analysis, CIMP+/*MLH1*-U status was a predictor of shorter DFS (*P* = 0.002; hazard ratio (HR) = 3.59, 95% CI, 1.59--8.08) and OS (*P* = 0.000; HR = 5.49, 95% CI, 2.21--13.62); lymphovascular invasion also predicted shorter OS (*P* = 0.047; HR = 2.13, 95% CI, 1.01--4.52). In multivariate analysis, only CIMP+/*MLH1*-U status independently predicted DFS (*P* = 0.011; HR = 3.16, 95% CI, 1.30--7.64) after adjusting for age, number of lymph nodes examined, pT4, and lymphovascular invasion and OS (*P* = 0.002; HR = 4.70, 95% CI, 1.74--12.72) after adjusting for age and lymphovascular invasion.

###### Univariate and multivariate Cox proportional hazard analysis of disease-free survival and overall survival

  Variable                  Total*n*   DFS                 OS                                                                                    
  ------------------------- ---------- ------------------- ------- ------------------- ------- -------------------- ------- -------------------- -------
  Age                                                      0.249                       0.262                        0.152                        0.100
   \< 60                    38         1.00 (Reference)            1.00 (Reference)            1.00 (Reference)             1.00 (Reference)     
   ≥ 60                     77         1.42 (0.78--2.57)           1.40 (0.77--2.57)           1.65 (0.83--3.26)            1.78 (0.90--3.54)    
  Sex                                                      0.396                                                    0.958                        
   Male                     52         1.00 (Reference)                                        1.00 (Reference)                                  
   Female                   63         1.26 (0.74--2.12)                                       0.98 (0.55--1.77)                                 
  Location                                                 0.948                                                    0.449                        
   Proximal                 58         1.00 (Reference)                                        1.00 (Reference)                                  
   Distal                   57         1.02 (0.60--1.72)                                       0.80 (0.44--1.43)                                 
  Lymph nodes examined                                     0.177                       0.108                        0.590                        
   ≥ 12                     80         1.00 (Reference)            1.00 (Reference)            1.00 (Reference)                                  
   \< 12                    35         1.46 (0.84--2.52)           1.61 (0.90--2.88)           1.19 (0.64--2.20)                                 
  Differentiation                                          0.415                                                    0.670                        
   Well to moderate         95         1.00 (Reference)                                        1.00 (Reference)                                  
   Poor                     20         0.73 (0.35--1.55)                                       0.84 (0.37--1.88)                                 
   pT4                                                     0.262                       0.456                        0.378                        
   No                       103        1.00 (Reference)            1.00 (Reference)            1.00 (Reference)                                  
   Yes                      12         0.56 (0.20--1.55)           0.67 (0.23--1.92)           0.63 (0.23--1.76)                                 
  Lymphovascular invasion                                  0.101                       0.193                        0.047                        0.200
   No                       95         1.00 (Reference)            1.00 (Reference)            1.00 (Reference)             1.00 (Reference)     
   Yes                      20         1.76(0.90--3.44)            1.64 (0.78--3.43)           2.13 (1.01--4.52)            1.73 (0.75--3.99)    
  Mucin production                                         0.422                                                    0.466                        
   No                       94         1.00 (Reference)                                        1.00 (Reference)                                  
   Yes                      21         1.29 (0.69--2.41)                                       1.29 (0.65--2.56)                                 
  *KRAS*                                                   0.524                                                    0.708                        
   Wild type                75         1.00 (Reference)                                        1.00 (Reference)                                  
   Mutant                   40         1.20 (0.69--2.07)                                       1.13 (0.61--2.08)                                 
  MSI status                                               0.470                                                    0.419                        
   MSS+MSI-low              59         1.00 (Reference)                                        1.00 (Reference)                                  
   MSI-high                 56         0.82 (0.48--1.40)                                       0.78 (0.43--1.42)                                 
  CIMP/*MLH1*                                              0.002                       0.011                        0.000                        0.002
   Others                   106        1.00 (Reference)            1.00 (Reference)            1.00 (Reference)             1.00 (Reference)     
   CIMP+/*MLH1***-**U       9          3.59 (1.59--8.08)           3.16 (1.30--7.64)           5.49 (2.21--13.62)           4.70 (1.74--12.72)   

Abbreviations: DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; CIMP, CpG island methylator phenotype; *MLH1*-M, *MLH1*-methylated; *MLH1*-U, *MLH1*-unmethylated; MSS, microsatellite stable; MSI, microsatellite instability. A backward elimination with threshold of *P* = 0.300 was used to select variables in the final models.

DISCUSSION {#s3}
==========

In this study, we examined differences in survival in a cohort of stage II CRC patients with different genetic and epigenetic tumor profiles. We found that classifying these tumors based on CIMP and *MLH1* methylation status created more uniform clinical CRC subsets that share common genetic features. Additionally, CIMP+/*MLH1*-U tumor status was associated with highly aggressive disease and poor prognosis in stage II CRC patients. Routine identification and further characterization of this tumor subtype might help to optimize CRC therapies and identify patients who may benefit from additional therapies.

Recently developed molecular classification systems will likely improve the stratification and treatment of CRC patients \[[@R7], [@R15]--[@R18]\]. In a previous study of the largest cohort of duodenal adenocarcinoma patients to date, we classified tumors into four subtypes based on the combination of CIMP and *MLH1* methylation status. The addition of this *MLH1* methylation status biomarker improved predictions of OS and time to recurrence in CIMP+ duodenal adenocarcinoma patients \[[@R14]\]. Furthermore, in a recent study of CIMP+ CRCs, OS decreased in *MLH1*-U patients compared to *MLH1*-M patients \[[@R19]\]. Here, we found that clinicopathologic features and survival rates also differed among stage II CRC patients assigned to different subgroups based on CIMP/*MLH1* methylation status.

CIMP−/*MLH1*-U tumors were the most common subtype, representing 67% of the study cohort. However, CIMP+ tumors, and especially CIMP+/*MLH1*-M tumors (\> 90 %), were more common than CIMP− tumors in older stage II CRC patients (≥ 60). A previous study revealed that CIMP+ tumors tend to have proximal locations \[[@R13]\]. Here, more than 90% of CIMP+/*MLH1*-M tumors were located in the proximal colon, whereas approximately 70% of CIMP−/*MLH1*-M tumors were located in the distal colon or rectum. However, CIMP+/*MLH1*-U tumors and CIMP−/*MLH1*-U tumors were evenly distributed in terms of proximal and distal location.

Both lymphovascular invasion and mucinous histology can be used to identify aggressive tumors and are indicative of unfavorable outcomes in CRC patients \[[@R20]--[@R22]\]. For example, lymphovascular invasion is associated with a high risk of lymph node metastasis even in T1 CRC patients \[[@R23]\]. Moreover, previous animal and clinical experiments have shown that increased production of mucin in human colon cancer cells correlates with increases in their metastatic potential and ability to colonize the liver \[[@R24]--[@R26]\]. Mucin production is also associated with CIMP+, MSI-H, and *BRAF* mutations in CRC \[[@R27]\]. Here, we found that CIMP+/*MLH1*-U tumors were associated with increased lymphovascular invasion and mucin production, which occurred in more than half of CIMP+/*MLH1*-U tumors and in less than one-fifth of tumors in the other groups. These findings suggest that CIMP+/*MLH1*-U status might identify a unique class of highly aggressive CRCs.

CIMP and *MLH1* methylation status are also associated with clinicopathologic and genetic differences in CRC as shown by Kim and colleagues \[[@R11]\]. In that study, CIMP+/*MLH1*-M tumors were associated with old age and proximal colonic tumor locations, while CIMP+/*MLH1*-U tumors were associated with vascular invasion, which is consistent with our results. However, conflicting data regarding associations between CIMP+/*MLH1*-M status and mucinous histology and between CIMP+/*MLH1*-U status and *KRAS* mutations have been reported; these associations were not detected in this study. These discrepancies may be explained by differences in patient populations, inclusion of different tumor stages, details of follow-up, and other factors associated with prognosis (such as chemotherapy and/or radiotherapy).

Analysis of individual biomarkers provides valuable predictive and prognostic information. Among the commonly analyzed biomarkers, MSI has been studied most extensively and is associated with survival in CRC patients \[[@R28]--[@R30]\]. A meta-analysis revealed that MSI-H CRCs were associated with a 40% improvement in OS compared to MSS tumors (95% CI, 0.31--0.47) \[[@R30]\]. The MSI-H tumor rate (48.7%) was relatively higher here than in previous studies; this difference might be explained at least in part by differences in inclusion criteria. Although the prognostic value of CIMP status in CRC has been inconsistent \[[@R31]--[@R35]\], a meta-analysis concluded that CIMP+ status was associated with poor prognosis in both MSI-high and MSS+MSI-low tumors \[[@R35]\]. Multiple studies support the feasibility of combining molecular markers to classify CRCs \[[@R32], [@R36]\]. Two studies in large population-based cohorts of individuals from the Colon Cancer Family Registry investigated associations between CIMP status and molecular features, risk factors, family history, and survival \[[@R37], [@R38]\]. Weisenberger *et al*. found that CIMP status was associated with MSI-H, *BRAF* mutation, proximal tumor sites, female patients, older age, and family history of CRC \[[@R37]\]. Furthermore, Phipps *et al*. found that survival differed among tumor subtypes defined by the combination of MSI, CIMP, *BRAF* mutation, and *KRAS* mutation status, which was derived from the classifications proposed by Samadder *et al*. \[[@R38], [@R39]\]. Patients with MSI-H disease subtypes (i.e., MSI-H, CIMP+, *BRAF* mutant, and *KRAS* wild-type tumors, and MSI-H, CIMP−, *BRAF* wild-type, and *KRAS* wild-type tumors) survived longest, and those with MSS or MSI-L, CIMP+, *BRAF* mutant, and *KRAS* wild-type tumors had the highest mortality \[[@R38]\]. However, this cohort included tumors of all stages, and the prognostic value of these classifications in stage II tumors requires further investigation.

Because the stage II CRC patients included in this study did not receive neoadjuvant chemotherapy, our survival analysis was not subject to potentially confounding prognostic factors related to this treatment. Among the four CIMP/*MLH1* methylation status groups, DFS and OS were shorter in the CIMP+/*MLH1*-U group than in the other three groups separately or combined. Most importantly, CIMP+/*MLH1*-U status was the only factor that independently predicted both DFS and OS after adjusting for other factors. Our findings, together with previous studies, demonstrate that novel subtype classifications may help to identify aggressive tumors and predict clinical outcomes.

The mechanisms by which *MLH1* methylation affects progression in stage II CRC remain unclear. MSI allows mutations to accumulate rapidly and facilitates tumor progression \[[@R40]\]; this high mutational load in MSI tumors typically creates 10 to 50 times more tumor-specific neoantigens than are found in MSS tumors \[[@R41]\]. Additionally, abnormalities in Human Leukocyte Antigen (HLA) class I expression are common in CRCs. Since HLA expression is required for the activation of tumor antigen-specific cytotoxic T-lymphocytes (CTL), HLA class I abnormalities allow tumors to circumvent immune surveillance. The ability to evade CTL activity may be especially important for MSI-H tumors, since they produce large amounts of neoantigens. Previous studies have demonstrated that HLA class I alterations are present in MSI-H tumors. For example, Dierssen *et al*. showed that distinct mechanisms are responsible for HLA class I loss in different tumor subtypes; loss of HLA class 1 expression was associated with the loss of β2m in HNPCC tumors and with APM component defects in MSI-H tumors \[[@R42]\]. Most sporadic, MSI-H CRC tumors are associated with alterations in *MLH1* methylation. Most strikingly, Scarpa *et al*. showed that patients with sporadic, MSI-H CRC had higher T-bet/CD4 ratios, CD80 expression rates, and CD8 lymphocyte infiltration compared to those with MSS tumors. Moreover, the Treg marker FoxP-3 was expressed in the MSS group, but not in the MSI-H group. Additionally, survival was better in stage I and II MSI-H patients with T-bet expression. Furthermore, *in vitro* experiments revealed that CD80 expression was higher in the HTC-15 cell line, which has a MSI-H status, than in the HT-29 MSS colon cancer cell line. When *MLH1* expression was inhibited in HT-29 cells, numbers of CD80+ cells increased \[[@R43]\]. Based on these results, we speculate that the importance of *MLH1* methylation for tumor classification may be due to variation in the causes of methylation in many cancer-specific genes, including *MLH1*, and to the distinct mechanisms underlying loss of HLA class I expression and enhanced immune surveillance in *MLH1*-M tumors.

In conclusion, the current results validate our novel classification strategy that uses CIMP and *MLH1* methylation status in combination to determine tumor subtypes in stage II CRC patients. CIMP+/*MLH1*-U tumors were the most aggressive and were associated with the poorest clinical outcomes, suggesting that new adjuvant therapies should be developed for this patient subgroup. Future investigations of the mechanisms underlying these associations will help improve the understanding of CRC tumorigenesis.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

This retrospective cohort study included patients with pathologically confirmed stage II (T1-4N0M0) CRC tumors who underwent radical resections at the Johns Hopkins Bayview Hospital (JHBH) and the Johns Hopkins Hospital (JHH) between 1995 and 2009. Patients who received neoadjuvant chemotherapy or for whom follow-up information, archival primary tumors, or corresponding matched normal samples were missing were excluded from the study. Formalin-fixed, paraffin-embedded (FFPE) colorectal cancer tissue and adjacent non-neoplastic colorectal tissue samples from 115 stage II colorectal cancer patients were obtained from JHBH and JHH with approval from the Institutional Review Board (IRB) and in accordance with Health Insurance Portability and Accountability Act (HIPAA) regulations. The histopathology of each specimen was examined to confirm the diagnosis.

*KRAS* mutation and MSI analysis {#s4_2}
--------------------------------

Genomic DNA from FFPE tissue was extracted using phenol chloroform, and polymerase chain reaction (PCR) targeting *KRAS* codons 12 and 13 was performed as previously described \[[@R44]\]. PCR products were sequenced in both directions using M13F (5′-GTAAAACGACGGCCAGT-3′) and R (5′-CAGGAAACAGCTATGACC-3′) primers (Agencourt Bioscience Corporation). Sequence data were analyzed using Sequencher 4.8 software (Gene Codes). All mutations were verified using bidirectional sequencing of a second PCR product derived independently from the original template.

MSI status was determined by examining D2S123, D5S346, D17S250, BAT25, and BAT26 \[[@R45]\]. Microsatellite sizes were compared with those of normal adjacent tissue, and tumors with instability in 2 or more of the markers were classified as high MSI (MSI-H). Tumors with instability in only 1 marker or without instability in these markers were classified as low MSI (MSI-L) or microsatellite stable (MSS), respectively.

Bisulfite modification and methylation analysis {#s4_3}
-----------------------------------------------

Purified DNA (2 mg) was bisulfite-treated and purified using the EZ DNA methylation kit (Zymo Research) according to the manufacturer\'s instructions. The 5-gene signature used to assess CIMP methylation status in primary tumor tissues consisted of *CACNA1G*, *IGF2*, *NEUROG1*, *RUNX3*, and *SOCS1* \[[@R13]\]. Methylation was quantified using MethyLight, a methylation-specific, probe based, real-time PCR technique \[[@R13], [@R46]\]. Alu was used as a normalization control reaction. All CIMP probes used a 5′ FAM fluorophore, a 3′ IBFQ quencher, and an internal ZEN quencher (Integrated DNA Technologies) \[[@R14]\]. DNA methylation is reported as percent of methylated reference (PMR) = 100 × \[(methylated reaction/Alu)~sample~/(methylated reaction/Alu)~M.SssI-reference~)\]. Markers were considered methylated when PMR = 10. Samples were considered CIMP+ if at least 3 of the 5 studied genes were methylated \[[@R13]\].

Statistical analysis {#s4_4}
--------------------

The primary clinical end point was DFS, which was measured from the date of surgery to the date of any event, regardless of cause \[[@R47]\]. Date of recurrence was established by radiographic studies, laboratory studies, physical examination, and/or histopathology. OS, defined as the time from surgery to death irrespective of cause, was a secondary outcome \[[@R47]\]. Statistical analysis was performed using SPSS software (version 18.0; SPSS, Chicago, IL). Clinicopathologic factors were compared using *χ2* tests with the Monte Carlo method or Fisher\'s exact test. Results were considered significant at *P \<* 0.05. Survival was estimated using the Kaplan-Meier method and log-rank test. Cox proportional hazard regression models were used to determine univariate and multivariate HRs.
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